Erasca (ERAS)
(Delayed Data from NSDQ)
$2.04 USD
+0.15 (7.94%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $2.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
ERAS 2.04 +0.15(7.94%)
Will ERAS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ERAS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ERAS
Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Best Momentum Stocks to Buy for April 23rd
ERAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for April 23rd
J&J (JNJ) Q2 Earnings & Sales Top, '23 View Upped, Stock Jumps
Merck (MRK) Keytruda Advanced Cervical Cancer Study Meets Goal
Other News for ERAS
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
Commit To Purchase Erasca At $1, Earn 10.3% Annualized Using Options
12 Health Care Stocks Moving In Friday's Pre-Market Session
Erasca’s Promising Naporafenib Data and Financial Stability Merit a Buy Rating
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Erasca (ERAS)